tetano
Editor, Senior Moderator
Biol Blood Marrow Transplant. 2010 Oct 12. [Epub ahead of print]
Seroprotective Titers against 2009-H1N1 Influenza A Virus after Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Issa NC, Marty FM, Gagne LS, Koo S, Verrill KA, Alyea EP, Cutler CS, Koreth J, Armand P, Ho VT, Antin JH, Soiffer RJ, Baden LR.
Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115.
Abstract
Little data are available regarding the safety and immunologic response to pandemic H1N1 influenza vaccine in allogeneic hematopoietic stem cell transplantation (HSCT) recipients. We measured serum antibody titers against A/California/7/2009 H1N1 using a hemagglutination inhibition (HAI) assay in 82 allogeneic HSCT recipients who received 2009-H1N1 vaccine between November 2009 and January 2010 after it became available at our institution. Median time between HSCT and vaccination was 19 months (range, 2.5-94) and from vaccination to specimen collection was 56 days (14-140). Seroprotective antibody titers (titer ≥1:40) against 2009-H1N1 influenza A virus were detected in 51% of the patients. The presence of chronic GVHD and type of conditioning regimen did not influence the rate of detecting seroprotective titers after vaccination. Patients were more likely to have seroprotective titers the further away from HSCT they were (adjusted odds ratio (OR) 1.79 per year; 95% CI, 1.12-2.85). Rituximab administration in the year preceding vaccination was associated with lack of seroprotective titers (OR 0.11; 95% CI, 0.01-0.97). The vaccine was safe and well tolerated. Strategies to improve influenza vaccine responses in this population are needed, especially in those who received immunotherapy.
Copyright ? 2010. Published by Elsevier Inc.
PMID: 20950701 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/20950701
Seroprotective Titers against 2009-H1N1 Influenza A Virus after Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Issa NC, Marty FM, Gagne LS, Koo S, Verrill KA, Alyea EP, Cutler CS, Koreth J, Armand P, Ho VT, Antin JH, Soiffer RJ, Baden LR.
Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115.
Abstract
Little data are available regarding the safety and immunologic response to pandemic H1N1 influenza vaccine in allogeneic hematopoietic stem cell transplantation (HSCT) recipients. We measured serum antibody titers against A/California/7/2009 H1N1 using a hemagglutination inhibition (HAI) assay in 82 allogeneic HSCT recipients who received 2009-H1N1 vaccine between November 2009 and January 2010 after it became available at our institution. Median time between HSCT and vaccination was 19 months (range, 2.5-94) and from vaccination to specimen collection was 56 days (14-140). Seroprotective antibody titers (titer ≥1:40) against 2009-H1N1 influenza A virus were detected in 51% of the patients. The presence of chronic GVHD and type of conditioning regimen did not influence the rate of detecting seroprotective titers after vaccination. Patients were more likely to have seroprotective titers the further away from HSCT they were (adjusted odds ratio (OR) 1.79 per year; 95% CI, 1.12-2.85). Rituximab administration in the year preceding vaccination was associated with lack of seroprotective titers (OR 0.11; 95% CI, 0.01-0.97). The vaccine was safe and well tolerated. Strategies to improve influenza vaccine responses in this population are needed, especially in those who received immunotherapy.
Copyright ? 2010. Published by Elsevier Inc.
PMID: 20950701 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/20950701